AOD-9604

AOD-9604 is a synthetic peptide that is a modified fragment of human growth hormone. It was developed to specifically target fat metabolism, aiming to promote fat breakdown and reduce new fat formation, without stimulating growth or affecting IGF-1 levels, which are associated with full-length growth hormone. Clinical studies have primarily shown a favorable safety profile. Across six human studies involving approximately 900 participants, AOD-9604 demonstrated a safety and tolerability profile similar to placebo. While it has been explored for weight management, its clinical efficacy in published human trials remains limited, and its use is currently considered experimental.

Targeted Fat Reduction: May help reduce fat in specific areas like the abdomen and thighs (Human Study).
Neutral on Glucose: Does not appear to negatively impact insulin or carbohydrate metabolism (Human Study).
Direct Fat Metabolism: May stimulate fat breakdown without affecting appetite (Animal Study).
No IGF-1 Effects: Does not promote growth or exhibit pro-diabetic effects (Human Study).
Glucose Handling: Some evidence suggests improved glucose processing in patients with impaired glucose tolerance (Human Study).
Oral Bioavailability: Can be absorbed orally, with tissue distribution similar to intravenous administration (Animal Study).
Safety Profile: Demonstrated safety comparable to placebo in human clinical trials (Human Study).
Low Immunogenicity: Did not lead to antibody formation in studies up to 24 weeks (Human Study).
Cartilage Support: Preclinical data suggest potential benefits for cartilage health (Animal Study).
Lean Mass Preservation: Observed fat loss without a decrease in muscle mass (Animal Study).

Ng, F.M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.
Stier, H., et al. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.
Moré, M.I., et al. (2014). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism, 4(3), 64-77.
Heffernan, M.A., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182-5189.
Johannsson, G., et al. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology & Metabolism, 82(3), 727-734.

$108.00

Per Unit

In stock